207 related articles for article (PubMed ID: 20351270)
1. Alternative splicing of human papillomavirus type-16 E6/E6* early mRNA is coupled to EGF signaling via Erk1/2 activation.
Rosenberger S; De-Castro Arce J; Langbein L; Steenbergen RD; Rösl F
Proc Natl Acad Sci U S A; 2010 Apr; 107(15):7006-11. PubMed ID: 20351270
[TBL] [Abstract][Full Text] [Related]
2. Human Papillomavirus 16 Oncoprotein Expression Is Controlled by the Cellular Splicing Factor SRSF2 (SC35).
McFarlane M; MacDonald AI; Stevenson A; Graham SV
J Virol; 2015 May; 89(10):5276-87. PubMed ID: 25717103
[TBL] [Abstract][Full Text] [Related]
3. The E7 oncoprotein is translated from spliced E6*I transcripts in high-risk human papillomavirus type 16- or type 18-positive cervical cancer cell lines via translation reinitiation.
Tang S; Tao M; McCoy JP; Zheng ZM
J Virol; 2006 May; 80(9):4249-63. PubMed ID: 16611884
[TBL] [Abstract][Full Text] [Related]
4. RNA interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53.
Sima N; Wang W; Kong D; Deng D; Xu Q; Zhou J; Xu G; Meng L; Lu Y; Wang S; Ma D
Apoptosis; 2008 Feb; 13(2):273-81. PubMed ID: 18060502
[TBL] [Abstract][Full Text] [Related]
5. Human Papillomavirus E6/E7 and Long Noncoding RNA TMPOP2 Mutually Upregulated Gene Expression in Cervical Cancer Cells.
He H; Liu X; Liu Y; Zhang M; Lai Y; Hao Y; Wang Q; Shi D; Wang N; Luo XG; Ma W; Zhang TC
J Virol; 2019 Apr; 93(8):. PubMed ID: 30728257
[TBL] [Abstract][Full Text] [Related]
6. E6^E7, a novel splice isoform protein of human papillomavirus 16, stabilizes viral E6 and E7 oncoproteins via HSP90 and GRP78.
Ajiro M; Zheng ZM
mBio; 2015 Feb; 6(1):e02068-14. PubMed ID: 25691589
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneous Nuclear Ribonucleoprotein A1 (hnRNP A1) and hnRNP A2 Inhibit Splicing to Human Papillomavirus 16 Splice Site SA409 through a UAG-Containing Sequence in the E7 Coding Region.
Zheng Y; Jönsson J; Hao C; Shoja Chaghervand S; Cui X; Kajitani N; Gong L; Wu C; Schwartz S
J Virol; 2020 Sep; 94(20):. PubMed ID: 32759322
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor induction of human papillomavirus type 16 E6/E7 MRNA in tumor cells involves two AP-1 binding sites in the viral enhancer.
Peto M; Tolle-Ersü I; Kreysch HG; Klock G
J Gen Virol; 1995 Aug; 76 ( Pt 8)():1945-58. PubMed ID: 7636475
[TBL] [Abstract][Full Text] [Related]
9. Cyclooxygenase-2 transcription is regulated by human papillomavirus 16 E6 and E7 oncoproteins: evidence of a corepressor/coactivator exchange.
Subbaramaiah K; Dannenberg AJ
Cancer Res; 2007 Apr; 67(8):3976-85. PubMed ID: 17440114
[TBL] [Abstract][Full Text] [Related]
10. Reversible repression of papillomavirus oncogene expression in cervical carcinoma cells: consequences for the phenotype and E6-p53 and E7-pRB interactions.
von Knebel Doeberitz M; Rittmüller C; Aengeneyndt F; Jansen-Dürr P; Spitkovsky D
J Virol; 1994 May; 68(5):2811-21. PubMed ID: 8151752
[TBL] [Abstract][Full Text] [Related]
11. Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways.
Goodwin EC; DiMaio D
Proc Natl Acad Sci U S A; 2000 Nov; 97(23):12513-8. PubMed ID: 11070078
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus type 16 E6 and E7 cooperate to increase epidermal growth factor receptor (EGFR) mRNA levels, overcoming mechanisms by which excessive EGFR signaling shortens the life span of normal human keratinocytes.
Akerman GS; Tolleson WH; Brown KL; Zyzak LL; Mourateva E; Engin TS; Basaraba A; Coker AL; Creek KE; Pirisi L
Cancer Res; 2001 May; 61(9):3837-43. PubMed ID: 11325860
[TBL] [Abstract][Full Text] [Related]
13. MiR-875 and miR-3144 switch the human papillomavirus 16 E6/E6* mRNA ratio through the EGFR pathway and a direct targeting effect.
Li Y; Cai Q; Lin L; Xu C
Gene; 2018 Dec; 679():389-397. PubMed ID: 30205176
[TBL] [Abstract][Full Text] [Related]
14. A transcriptomic landscape of human papillomavirus 16 E6-regulated gene expression and splicing events.
Xu J; Fang Y; Qin J; Chen X; Liang X; Xie X; Lu W
FEBS Lett; 2016 Dec; 590(24):4594-4605. PubMed ID: 27859058
[TBL] [Abstract][Full Text] [Related]
15. HPV16 oncogenes E6 or/and E7 may influence the methylation status of RASSFIA gene promoter region in cervical cancer cell line HT-3.
Yin F; Wang N; Wang S; Yu F; Sun X; Yu X; Luo B; Zhao C; Wang Y
Oncol Rep; 2017 Apr; 37(4):2324-2334. PubMed ID: 28260046
[TBL] [Abstract][Full Text] [Related]
16. [Human papillomavirus type 16 E6 oncogene and expression of P53, RB and PCNA in human cervical carcinoma].
Bian J; Yu X; Dong J; Zhao W; Zhou Y; Luan Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Sep; 11(3):271-3. PubMed ID: 15617346
[TBL] [Abstract][Full Text] [Related]
17. The full-length E6 protein of human papillomavirus type 16 has transforming and trans-activating activities and cooperates with E7 to immortalize keratinocytes in culture.
Sedman SA; Barbosa MS; Vass WC; Hubbert NL; Haas JA; Lowy DR; Schiller JT
J Virol; 1991 Sep; 65(9):4860-6. PubMed ID: 1651408
[TBL] [Abstract][Full Text] [Related]
18. Expression of epidermal growth factor receptor and human papillomavirus E6/E7 proteins in cervical carcinoma cells.
Hu G; Liu W; Mendelsohn J; Ellis LM; Radinsky R; Andreeff M; Deisseroth AB
J Natl Cancer Inst; 1997 Sep; 89(17):1271-6. PubMed ID: 9293917
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo growth inhibition of human cervical cancer cells via human papillomavirus E6/E7 mRNAs' cleavage by CRISPR/Cas13a system.
Chen Y; Jiang H; Wang T; He D; Tian R; Cui Z; Tian X; Gao Q; Ma X; Yang J; Wu J; Tan S; Xu H; Tang X; Wang Y; Yu Z; Han H; Das BC; Severinov K; Hitzeroth II; Debata PR; Xu W; Fan W; Jin Z; Cao C; Yu M; Xie W; Huang Z; Hu Z; You Z
Antiviral Res; 2020 Jun; 178():104794. PubMed ID: 32298665
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus type 16 E6 and E7 oncoproteins interact with the nuclear p53-binding protein 1 in an in vitro reconstructed 3D epithelium: new insights for the virus-induced DNA damage response.
Squarzanti DF; Sorrentino R; Landini MM; Chiesa A; Pinato S; Rocchio F; Mattii M; Penengo L; Azzimonti B
Virol J; 2018 Nov; 15(1):176. PubMed ID: 30445982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
